16 Jan The manufacturer of Nexplanon®and Implanon® has issued updated guidance regarding the recommended insertion site
Please find here the link to the letter from MSD:
Implanon NXT– etonogestrel 68 mg, implant for subdermal use -Update to the insertion and removal instructions to minimise the risks of neurovascular injury and implant migration
FSRH published a CEU Statement on Nexplanon® Insertion Site (15 January 2020)
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.